Markets

Health Care Sector Update for 10/06/2015: CPRX, INFI, FATE

Top Health-care stocks:

JNJ: flat

PFE: flat

ABT: flat

MRK: flat

AMGN: +1.3%

Health-care shares were generally unchanged in pre-market trade Tuesday.

In health-care stocks news, Catalyst Pharmaceutical Partners ( CPRX ) a biopharmaceutical company focused on developing and commercializing therapies for people with rare debilitating diseases, announced Tuesday a clinical trial with Firdapse (amifampridine phosphate) in pediatric patients with congenital myasthenic syndromes ( CMS ).

Shares in the company were unchanged at $2.99 pre-bell. Over the past 52 weeks, the company has traded between $2.26 and $5.80.

Infinity Pharmaceuticals ( INFI ) said it expects topline data from its phase 2 trial of duvelisib to treat indolent non-Hodgkin lymphoma by Q3 of 2016 and expects to submit regulatory filings by the end of 2016.

Shares in the company were also unchanged at $8.83 pre-bell. Over the past 52 weeks, the company has traded between $7.56 and $18.25.

And Fate Therapeutics ( FATE ) shares were initiated by Raymond James with an outperform rating and $8 price target.

The company was flat pre-bell at $5.80. The company has traded between $3.50 and $8.78 over the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CPRX INFI CMS FATE

Other Topics

Commodities

Latest Markets Videos

    MTNewswires

    Founded in 1999, MT Newswires (formerly known as Midnight Trader) is a leading provider of original source, multi-asset class, real-time, global financial news and information to most of the largest banks, brokerage firms and professional market data, trading & research applications in North America.

    Learn More